The Supreme Court declined to hear Teva’s challenge to a $235 million award to GSK in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva’s appeal of a lower court’s ruling reinstating the jury award for U.K.-based GSK. (Reuters)

President Biden nominated Monica Bertagnolli to run the National Institutes of Health. The NIH director position has been empty since Francis S. Collins stepped down in December 2021 after a 12-year tenure. (The Washington Post)

Athenex filed for Chapter 11 bankruptcy and is seeking a buyer for its drug candidates. Chief Executive Dr. Johnson Lau said the company had succeeded in bringing tirbanibulin, a treatment for actinic keratosis through regulatory approvals, to the U.S. market and a number of EU countries, as well as Taiwan. (MarketWatch)

CVS said it will shut down its clinical trials unit that was launched during the COVID-19 pandemic. It wasn’t immediately clear exactly how many employees will be affected and a spokesperson said CVS would work with trial sponsors to coordinate the wind-down as well as try to place affected employees in other parts of the company. (Endpoints News)

Gilead Sciences said that an expanded research deal with Arcus Biosciences (RCUS) would reduce its 2023 GAAP and non-GAAP earnings. The two organizations said they are expanding a cancer study collaboration. (Seeking Alpha)